A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  European Journal of Obstetrics, Gynecology, and Reproductive Biology

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejogrb.2013.12.001PMID 24405730
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.

  2016cited by this paper
• Prevention and management of ovarian hyperstimulation syndrome.

  2012cited by this paper
• Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles? A randomized controlled study.

  2012cited by this paper
• GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes.

  2012cited by this paper
• Cabergoline for preventing ovarian hyperstimulation syndrome.

  2012cited by this paper
• Gonadotrophin-releasing hormone antagonists for assisted reproductive technology in women with poor ovarian response. subgroup analysis of cochrane systematic review and meta-analysis

  2011cited by this paper
• Gonadotrophin-Releasing Hormone Antagonists for Assisted Reproductive Technology

  2011cited by this paper
• Prevention of OHSS: GnRH agonist versus HCG to trigger ovulation

  2009cited by this paper
• Pathophysiologic features of "thin" endometrium.

  2009cited by this paper
• Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.

  2008cited by this paper
• Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome

  2007cited by this paper
• Low-dose HCG is useful in preventing OHSS in high-risk women without adversely affecting the outcome of IVF cycles.

  2007cited by this paper
• Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome.

  2005cited by this paper
• Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.

  2004cited by this paper
• Effect of angiotensin-converting enzyme-inhibiting therapy on the expression of vascular endothelial growth factor in hyperstimulated rat ovary.

  2004cited by this paper
• Administration of Moderate and High Doses of Gonadotropins to Female Rats Increases Ovarian Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor-2 Expression that Is Associated to Vascular Hyperpermeability1

  2003cited by this paper
• Expression of vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnancy.

  2002cited by this paper
• Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells.

  1999cited by this paper
• Gonadotropin-releasing hormone agonist has the ability to induce increased matrix metalloproteinase (MMP)-2 and membrane type 1-MMP expression in corpora lutea, and structural luteolysis in rats.

  1999cited by this paper
• The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor.

  1999cited by this paper
• Genomic and non-genomic mechanisms of oxytocin receptor regulation.

  1998cited by this paper
• The kallikrein-kinin system, but not vascular endothelial growth factor, plays a role in the increased vascular permeability associated with ovarian hyperstimulation syndrome.

  1998cited by this paper
• Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome.

  1998cited by this paper
• Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells

  1998cited by this paper
• Regulation of follicular luteinization by a gonadotropin‐releasing hormone agonist: Relationship between steroidogenesis and apoptosis

  1998cited by this paper
• Prorenin and active renin concentrations in plasma and ascites during severe ovarian hyperstimulation syndrome.

  1997cited by this paper
• Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells.

  1997cited by this paper
• Role of progesterone in capillary permeability in hyperstimulated rats.

  1997cited by this paper
• The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.

  1997cited by this paper
• Endocrinology: Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome

  1996cited by this paper
• Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome.

  1996cited by this paper
• Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome.

  1994cited by this paper
• Molecular cloning and expression of a rat Via arginine vasopressin receptor

  1992cited by this paper
• Molecular cloning of the receptor for human antidiuretic hormone

  1992cited by this paper
• Evidence for widespread atresia in the hypophysectomized estrogen-treated rat.

  1987cited by this paper
• Ovarian Hyperstimulation Syndrome: A Current Survey

  1978cited by this paper
• Ovarian hyperstimulation syndrome: a current survey.

  1978cited by this paper
• Interactions between peripheral and hypothalamic carbachol stimulation of drinking in the rat.

  1974cited by this paper

• Ovarian Hyperstimulation Syndrome (OHSS) requiring Intensive Care Unit (ICU) admission between 1996-2020 in England, Wales, and Northern Ireland

  2022cites this paper
• Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model

  2022cites this paper
• Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS).

  2021cites this paper
• Ovarian Hyperstimulation Syndrome

  2020cites this paper
• Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model.

  2020cites this paper
• Sp1 regulates steroidogenic genes and LHCGR expression in primary human luteinized granulosa cells.

  2019cites this paper
• The effects of resveratrol on ovarian hyperstimulation syndrome in a rat model.

  2018cites this paper
• Inhibition of RM-1 prostate carcinoma and eliciting robust immune responses in the mouse model by using VEGF-M2-GnRH3-hinge-MVP vaccine

  2018cites this paper
• Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome

  2018cites this paper
• Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management

  2018cites this paper
• Aromatase Inhibitors Versus Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome: a Prospective, Randomized, Double-Blind Study

  2017cites this paper
• GnRH Antagonist Cetrorelix Administration Before hCG for Protection of Ovarian Hyperstimulation Syndrome

  2017cites this paper
• Friends Turned Foes: Angiogenic Growth Factors beyond Angiogenesis

  2017cites this paper
• Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders.

  2017cites this paper
• The high responder: a review of pathophysiology and outcomes during IVF treatment

  2017cites this paper
• Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial

  2016cites this paper
• Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist

  2015cites this paper
• Prevention of Ovarian Hyperstimulation Syndrome: A Review

  2015cites this paper
• The effects of formoterol on the serum, peritoneal VEGF, MDA, and VEGF levels in the ovaries and endometrium of rats with OHSS.

  2015cites this paper
• Approaches to complete prevention of OHSS

  2014cites this paper